Balyasny Asset Management LLC Dia Medica Therapeutics Inc. Transaction History
Balyasny Asset Management LLC
- $63.6 Billion
- Q4 2024
A detailed history of Balyasny Asset Management LLC transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 14,581 shares of DMAC stock, worth $89,818. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,581Holding current value
$89,818% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DMAC
# of Institutions
49Shares Held
5.27MCall Options Held
8.9KPut Options Held
200-
Vanguard Group Inc Valley Forge, PA1.24MShares$7.65 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$5.17 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX515KShares$3.17 Million6.41% of portfolio
-
Bleichroeder LP New York, NY382KShares$2.36 Million0.63% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA375KShares$2.31 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $163M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...